SEC Form 4 · accession 0001144204-15-070834
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yossi Maimon
Officer — Vice President & CFO
Period of report
Dec 14, 2015
Accepted (ET)
Dec 15, 2015 · 7:30 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001006281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2015 | P | 10,000 | $0.78 | A | 10,000 | D | |
| Common StockF1,F2 | holding | — | — | — | 185,000 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., issued under its 2006 Stock Incentive Plan, as amended June 17, 2012 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. In addition to the vesting period, vested restricted shares will be subject to a lock-up for a 24-month period commencing upon the vesting date. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control or Corporate Transaction, each as defined in the Plan, and the lock-up periods will terminate.
- F2To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.